{"denoms":[{"counts":[{"groupId":"BG000","value":"335"}],"units":"Participants"}],"groups":[{"description":"Participants received rituximab 1 g intravenously (IV) on Days 1 and 15 of each course of retreatment. In addition, participants received methotrexate 10-25 mg/week orally or parenterally, methylprednisolone 100 mg IV 30 minutes prior to both rituximab infusions, and a stable dose of folic acid ≥ 5 mg/week or equivalent, given as either a single dose or as divided daily doses.","id":"BG000","title":"Rituximab"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"11.81","value":"53.1"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"273"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"62"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}],"populationDescription":"Safety population: All participants who received any part of an infusion of study medication."}